TREATMENT OF PROSTATE CANCER
Disclosed herein are methods of treating a patient in need of therapy for prostate cancer comprising delivering a β-radiation-emitting composition into the prostatic vasculature. In some embodiments, an absorbed dose of 60 Gy to 200 Gy is delivered to the prostate. In some embodiments, the β-radiation-emitting composition is delivered into the arterial vasculature of the prostate via a catheter. In some embodiments, the β-radiation-emitting composition comprises a suspension of the β-radiation-emitting particles in an aqueous liquid.
1 . A method of treating a patient in need of therapy for prostate cancer comprising delivering a β-radiation-emitting composition into the prostatic vasculature.
2 . The method of claim 1 , wherein an absorbed dose of 60 Gy to 200 Gy is delivered to the prostate.
3 . The method of claim 1 , wherein the β-radiation-emitting composition is delivered into the arterial vasculature of the prostate.
4 . The method of claim 1 , wherein the β-radiation-emitting composition is delivered by injection.
5 . The method of claim 1 , wherein the β-radiation-emitting composition is delivered through a catheter.
6 . The method of claim 1 , further comprising constricting the urethral vasculature of the patient while delivering the β-radiation-emitting composition.
7 . The method of claim 1 , wherein the β-radiation composition contains one or more radionuclides selected from 89 Sr, 166 Ho, 153 Sm, 177 Lu, 169 Er and 90 Y.
8 . The method of claim 1 , wherein the β-radiation-emitting composition comprises β1-radiation-emitting particles that have mean diameter of 5 to 100 µm.
9 . The method of claim 8 , wherein the β-radiation-emitting composition comprises a suspension of the β-radiation-emitting particles in an aqueous liquid.
10 . The method of claim 8 , wherein the β-radiation-emitting particles comprise glass particles, polymer particles, or oil particles.
11 . The method of claim 8 , wherein the β-radiation-emitting particles comprise insoluble glass microspheres.
12 . The method of claim 11 , wherein each milligram of glass contains between 22,000 and 73,000 microspheres.
13 . The method of claim 8 , wherein the β-radiation-emitting particles comprise insoluble glass microspheres having yttrium-90 ( 90 Y) as an integral constituent of the glass.
14 . The method of claim 8 , wherein the β-radiation-emitting particles have a specific activity when administered ranging from 0.0002 to 0.05 GBq/mg.
15 . The method of claim 1 , wherein the β-radiation-emitting composition comprises β-radiation-emitting microspheres that have a specific activity per microsphere, when administered, of 5000 to 10 Bq and/or wherein the β-radiation-emitting composition comprises β-radiation-emitting microspheres that result in a number of microspheres per mL of prostate tissue of 1,000 to 40,000.
16 . The method of claim 1 , wherein the β-radiation-emitting composition is used in combination with externally applied radiation therapy.
17 . The method of claim 1 wherein the prostatic vasculature is embolized to isolate the prostatic arteries.
18 . The method of claim 1 , wherein dose delivery is confirmed with post-Y90 PET and used to plan subsequent therapy.
19 . A method of treating a patient in need of therapy for prostate cancer comprising delivering a β-radiation-emitting composition that comprises β-radiation-emitting particles through a catheter into the arterial vasculature of the prostate, wherein the urethral vasculature of the patient is constricted while delivering the β-radiation-emitting composition, and wherein an absorbed dose of 60 Gy to 200 Gy is delivered to the prostate.
20 . A method of treating a patient in need of therapy for prostate cancer comprising delivering a β-radiation-emitting composition that comprises β-radiation-emitting particles through a catheter into the arterial vasculature of the prostate, wherein the prostatic vasculature is embolized to isolate the prostatic arteries, and wherein an absorbed dose of 60 Gy to 200 Gy is delivered to the prostate.